[exclusive] positive results of Tadanafil Asian male trial

Introduction: on October 25, 2018, International Journal of Urology published the results of randomized, double-blind, parallel group control study led by the First Affiliated Hospital of Peking University and participated by research institutions from mainland China, Taiwan, South Korea and other regions to evaluate the ineffectiveness and safety of tadara in specific male population in Asia In this phase III clinical trial (nct01937871), 909 Asian men with lower urinary tract symptoms caused by BPH and erectile dysfunction were randomly divided into placebo group (n = 361), tadalafil 5mg (n = 362) or tamoxin 0.2mg group (n = 185) in a ratio of 2:2:1 After 12 weeks of continuous treatment, the international prostate symptom score and international erectile dysfunction in tadalafil group were compared The improvement of iief-ef score compared with baseline was significantly better than that of placebo group (5.49 vs-4.08, P0.05, respectively) After 6 months of treatment, the above indexes of placebo group were significantly higher than those of tadalafil group, which confirmed the effectiveness and safety of tadalafil 5mgqd in the treatment of premature ejaculation (6) To investigate the efficacy and safety of tadalafil in the treatment of erectile dysfunction after ns-rarp [source] sexmed.2018jun; 6 (2): 108-114 [experimental design] retrospective study [basic information of subjects] 95 men who received ns-rarp and took tadalafil 5mgqd for penile recovery [treatment] group 1: tadalafil 5mgqd for 2 years; group 2: tadalafil 10mgqd for 1 year; group 3: no tadalafil treatment [main results] all IIEF-5 scores of the subjects in group 1 were significantly improved (P < 0.0001) There was no significant difference in the recovery of erectile function between group 1 and group 2 after 2 years of follow-up The results of subgroup analysis showed that there was no significant difference in the recovery of erectile function among the subjects with different ns status, but the improvement of erectile function in group 1 was better than that in group 2 The improvement effect of intravenous erectile dysfunction was worse than that of arterial erectile dysfunction (14.2% vs 55.5% vs 53.3%) Safety: the main adverse reactions and their overall incidence included facial redness (9.5%), headache (7.1%) and vertigo (2.3%) [main conclusion] although the effect of Tadanafil 5mgqd in the patients with venous erectile dysfunction is not as good as that in the patients with arterial erectile dysfunction, the drug has a good tolerable feature in the two years after ns-rarp and can improve the erectile function of the patients after operation (7) To compare the safety and efficacy of selodoxin, solinacin, tadalafil and their combination in the treatment of DJ stent related lower urinary tract symptoms [source] turkishjournal of urology.2018,44 (3): 228-238 [test design] prospective and randomized test [basic data of subjects] 335 patients who received DJ stent and had stent related symptoms one week after operation were enrolled in the group [group and intervention method] group 1: cilotoxin (8mgqd) + sulindanin (10mgqd) + tadalafil (5mgqd); group 2: cilotoxin, 8mgqd; group 3: sulindanin, 10mgqd; group 4: tadalafil, 5mgqd; group 5: cilotoxin (8mgqd) + sulindanin (10mgqd); group 6: cilotoxin (8mgqd) + tadalafil (5mgqd); Group 7: solanesin (10mgqd) + tadalafil (5mgqd) Group 8: placebo [main results] there was no significant difference in the results of the first week of ureteral stent symptom questionnaire (ussq) among the groups, but after three weeks of treatment, the ussq scores of group 1 to group 7 were significantly lower than that of group 8 (placebo) However, the ussq score of group 5 (sirodoxin + solinacin) was better than that of other treatment groups, and the quality of life score of group 5 was also better than that of other treatment groups [main conclusion] the effect of the combination of selodoxin and solinacin in improving SRS is better than that of the treatment with tadalafil (8) to investigate the effectiveness of tamsulosin on the treatment of acute urinary retention in patients with benign prostatic hyperplasia (TBL), based on tamsulosin (Research Institute) * Boozer Medical University, India [source] urologia 2018; 85 (2): 51-54 [trial design] randomized, double-blind, placebo-controlled trial [subjects] * a total of 80 patients with acute prostatic hyperplasia associated with acute urinary retention were enrolled [grouping and intervention] group 1: tamoxin 0.4mgqd + placebo; group 2: tadalafil 10mgqd + tamoxin 0.4mgqd, both groups were treated for 7 consecutive days [main results] 23 (57.5%) and 26 (65%) subjects in group 1 and group 2 successfully urinated after removing the catheter (P = 0.491, indicating no significant difference between the groups) After 7 days of treatment, 29 (72.5%) and 26 (65%) subjects in group 1 and group 2 could urinate, and there was no significant difference between the groups * conclusion: adding talalapril on the basis of alpha blockers improves the effect of tamsulosin alone in improving the symptoms of acute urinary retention associated with benign prostatic hyperplasia (9) To investigate the safety and efficacy of tadalafil 5mgqd in patients with benign prostatic hyperplasia / hypospadias [source] worldjournal of men's health.2018,36 (2): 161-170 [experimental design] single country, prospective, observational cohort study [basic information of subjects] patients with BPH / hypospadias in Korea who were treated with tadalafil 5mgqd, 637 in the safety analysis group, 265 in the effectiveness analysis group (week 12) and 44 in the effectiveness Analysis Group [observation duration] were followed up for 12 ± 2 weeks and 24 ± 2 weeks respectively [main results] after 12 and 24 weeks of treatment, the mean IPSS was significantly improved by 4.7 ± 0.3 and 6.4 ± 0.7 points (P < 0.0001) compared with the baseline, while the urine storage, micturition and quality of life were also significantly improved As a whole, 69.1% of the patients with clinical significance (≥ 3 points) of partial improvement of IPSS Safety: 13 subjects (2%) had 15 treatment-related adverse events, including 10 mild adverse events and 5 moderate adverse events No serious treatment-related adverse reactions or serious adverse reactions were found [main conclusion] in the real world, tadalafil 5mg QD is safe and effective in Korean patients with BPH / hypospadias 3.2 safety of special population (1) safety of tadalafil in the treatment of precursory epilepsy [Research Institute] Japan triple Medical University [source] Journal of material fatal & neurological medicine.2018, jun22 Published in advance [experimental design] single group observational study [group and intervention] single group, tadalafil treatment, dose increase, 10 mg QD ~ 40 mg QD [basic information of subjects] 8 patients with preeclampsia [main results] tadalafil had no adverse reactions in the maternal body at the dose of 10mgqd; even at the dose of 20mgqd, only two subjects had grade 1 headache, one subject had grade 1 palpitation; at the dose of 40mgqd, one subject had grade 1 headache Moreover, the adverse reactions can disappear within 3 days No fetal adverse reactions were found All the observed adverse reactions in neonates were considered to be caused by preterm delivery, but not by tadalafil [main conclusion] tadalafil is well tolerated in the treatment of preeclampsia Although the incidence of adverse reactions increased with the increase of dose, all the adverse reactions were mild, and all the doses had good safety for the mother and fetus 4 Sum up that tadalafil is the second globally listed erectile dysfunction treatment drug developed by Lilly company after sildenafil, whose global sales have surpassed the latter However, with the expiration of its core patents, generic drugs have been listed in various markets, including the United States, which has a certain impact on the original research market of tadalafil The latest published clinical trials related to tadalafil are also rare In China, because the patent of tadalafil core compound has expired in 2015, the wave of its imitation has already begun, and there are many domestic publicizing, launching and even completing be test It can be expected that in the future, the market competition of tadalafil will be no less intense than that of xidenafil Statement: this opinion only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.